Real-World Evidence: Promise and Peril For Medical Product Evaluation
- PMID: 30100687
- PMCID: PMC6065494
Real-World Evidence: Promise and Peril For Medical Product Evaluation
Abstract
Randomized controlled trials have long been the gold standard for evidence in medical product evaluation, but there is growing support for the use of real-world evidence (RWE). The authors review the benefits and limitations of RWE and discuss the implications for P&T committees.
References
-
- Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297. - PubMed
-
- Institute of Medicine. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC: National Academies Press (US), National Academy of Sciences; 2010. The National Academies Collection: Reports funded by National Institutes of Health. - PubMed
-
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33. - PubMed
-
- Sertkaya A, Wong HH, Jessup A, Beleche T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016;13(2):117–126. - PubMed
LinkOut - more resources
Full Text Sources